Biomarker Insights最新文献

{"title":"<i>Staphylococcus aureus</i>-derived Signature Protein(s) in Murine Vaginal Lavage Fluid: Investigating the Underlying factors of Infertility as a Consequence of Sperm Impairing Bacterium.","authors":"Ishwerpreet Kaur Jawanda, Thomson Soni, Seema Kumari, Vijay Prabha","doi":"10.1177/11772719251340518","DOIUrl":"10.1177/11772719251340518","url":null,"abstract":"<p><strong>Background: </strong>Bacterial infections are often an overlooked factor in female infertility. <i>Staphylococcus aureus</i> has been identified as the predominant vaginal pathogen in infertile women, with a prevalence of 57.33%. Previous studies showed that <i>S. aureus</i> induces infertility in mice by sperm impairment, suggesting its asymptomatic vaginal colonization creates a hostile environment for sperm. While sperm immobilization factor (SIF) from culture supernatant has been identified, its production within host's environment remained unexplored.</p><p><strong>Objective: </strong>To unveil <i>S. aureus</i>-derived signature protein(s) in vaginal lavage fluid (VLf).</p><p><strong>Design: </strong>Mass spectrometry combined with experimental studies.</p><p><strong>Methods: </strong>VLf was obtained from female mice administered either with sperm immobilizing <i>S. aureus</i> (test group) or PBS alone (control group) and analyzed using nano-LC-MS/MS, gel filtration chromatography, SDS-PAGE, functional assays, and in silico studies.</p><p><strong>Results: </strong>Nano-LC-MS/MS yielded 5 distinct bacterial proteins in test group and no bacterial protein in control. Elution profile of test VLf revealed a single peak and indicated 1 protein band (~36 kDa) using SDS-PAGE that aligned with GMP reductase. VLf-protein showed impairment of sperm motility and viability in concentration-dependent manner and disrupted sperm morphology. Binding studies using FITC-labeled VLf-protein depicted presence of green fluorescence over entire surface of mouse spermatozoa. These results were akin to SIF, already isolated and characterized in our laboratory, from culture supernatant of <i>S. aureus</i>, causing sperm impairment and hence, designated as vaginal lavage fluid-derived sperm immobilization factor (VLf-SIF). Through in silico analysis, superimposition of VLf-SIF and SIF, already known to show sequence homology to cysteine-tRNA ligase, revealed close structural alignment. Molecular docking analysis depicted energetically favorable binding between VLf-SIF and spermatozoa surface protein (Heat shock-related 70 kDa protein 2).</p><p><strong>Conclusion: </strong>This study provides novel evidence of sperm-impairing <i>S. aureus</i> signature proteins as key mediators of bacterial-induced infertility, paving way for diagnostic, and therapeutic advancements.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251340518"},"PeriodicalIF":3.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest Advances in Structural Insights and Quantification Techniques for Type I Collagen Biomarkers: A path toward standardization?","authors":"Justine Demeuse, Alix Mackowiak, Elodie Grifnée, Philippe Massonnet, Loreen Huyghebaert, Thomas Dubrowski, Stéphanie Peeters, Caroline Le Goff, Etienne Cavalier","doi":"10.1177/11772719251336274","DOIUrl":"10.1177/11772719251336274","url":null,"abstract":"<p><p>With an aging population, the demand for sensitive and specific biomarkers to assess bone turnover has surged. Bone turnover involves 2 key processes: bone formation, during which Type I procollagen is cleaved into Type I collagen and subsequently mineralized into bone, and bone resorption, during which Type I collagen is demineralized and degraded into peptides by cathepsin K. To identify biomarkers that accurately reflect these processes, extensive efforts have been made to characterize the peptides generated during both formation and resorption. Over the years, numerous biomarkers have been discovered for various disorders. However, despite their clinical utility, many of these markers lack specificity. This is due to factors such as the degradation of trimers into monomers, the coexistence of multiple peptide species arising from the unpredictable cleavage of Type I collagen/procollagen by cathepsin K and metalloproteinases, and the lack of assay standardization. Standardization is further hindered by the incomplete characterization of many of these peptides. For accurate assay development, a gold-standard technique like LC-MS/MS is essential, requiring full peptide characterization during method development. This review aims to present recent advances in the characterization of Type I collagen-derived peptides, providing a foundation for improved biomarker standardization and application in clinical practice.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251336274"},"PeriodicalIF":3.4,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-diagnostic Demographic, Lifestyle, and Health History Factors in Association with Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression in Colorectal Cancer Tissue.","authors":"Umaimah Zanif, Jaclyn Parks, Isabella Tai, Stephen Yip, Sindy Babinszky, Katy Milne, Peter Watson, Rachel A Murphy, Parveen Bhatti","doi":"10.1177/11772719251339955","DOIUrl":"10.1177/11772719251339955","url":null,"abstract":"<p><strong>Background: </strong>Demographic, health history, and lifestyle factors have been associated with prognosis of colorectal cancer (CRC), but mechanisms underlying these associations remain poorly understood. A compelling mechanism involves changes in expression of tumor markers that influence treatment outcomes, such as secreted protein acidic and rich in cysteine (SPARC), lower levels of which have previously been associated with poorer CRC prognosis.</p><p><strong>Objective: </strong>We explored the association of factors that have been previously associated with CRC prognosis with expression of SPARC in tumor tissues.</p><p><strong>Design: </strong>We conducted a prospective evaluation of 50 participants of a longitudinal cohort study that went on to develop CRC.</p><p><strong>Methods: </strong>Tumor and normal tissue cores were taken from formalin-fixed paraffin-embedded (FFPE) blocks of incident CRC cases and were used to create tissue microarrays (TMAs). Slides created from the TMAs were stained with SPARC antibodies and analyzed to calculate H-scores for both epithelial and non-epithelial components of tumor and normal tissues. H-scores were ln-transformed and analyzed in association with demographic, lifestyle, and health history factors assessed before cancer diagnosis using linear regression models.</p><p><strong>Results: </strong>In CRC tumor epithelium, smoking was associated with a 0.53-fold lower level of SPARC expression (<i>P</i> = .054). Higher income was associated with a 1.33-fold greater level of SPARC expression in tumor non-epithelial tissue (<i>P</i> = .041). Higher cancer stage was associated with a 0.74-fold lower level of non-epithelial tumor SPARC expression (<i>P</i> = .040). In the epithelial component of normal colorectal tissues, higher fruit consumption was associated with a 2.74-fold greater SPARC H-score (<i>P</i> = .002).</p><p><strong>Conclusions: </strong>The associations we observed for smoking, income, and cancer stage with SPARC in tumor tissue are consistent with previously established associations of these factors with CRC prognosis. Larger studies with prognostic data are needed, but our results suggest that differences in SPARC expression may contribute to previously observed impacts of various factors on CRC prognosis.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251339955"},"PeriodicalIF":3.4,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor Abilities of Noninvasive Biomarkers to Assess Esophagogastric Varices and Portal Hypertensive Gastropathy.","authors":"Kodjo Kunale Abassa, Xiaoning Guo, Shuyan Tan, Zhiling Liang, Siwei Tan","doi":"10.1177/11772719251339185","DOIUrl":"10.1177/11772719251339185","url":null,"abstract":"<p><strong>Background: </strong>Noninvasive and cost-effective markers are needed to replace esophagogastroduodenoscopy in the screening for severe esophagogastric varices (EGVs) and portal hypertensive gastropathy (PHG).</p><p><strong>Objective: </strong>This study evaluated the performances of several commonly used fibrosis markers in assessing EGVs and PHG in cirrhosis patients.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>A series of 323 patients with cirrhosis were consecutively enrolled and endoscopically followed up until variceal eradication was achieved. The Fibrosis-4 (FIB-4) score, albumin-bilirubin (ALBI) index, aspartate aminotransferase (AST)-to-alanine aminotransferase (ALT) ratio (AAR), AST-to-platelet ratio index (APRI), gamma-glutamyl transpeptidase-to-platelet ratio (GPR), and Lok score were calculated for each patient upon first admission. The performances of these markers in assessing EGVs and PHG were determined.</p><p><strong>Results: </strong>In the screening for clinically relevant esophageal varices (CREVs), none of the markers showed a significant ability to differentiate CREVs from non-CREVs (<i>P</i> > .05). The AAR (area under the curve (AUC): 0.581, sensitivity: 52.0%, specificity: 66.1%, <i>P</i> = .033) and the GPR (AUC = 0.596, sensitivity: 64.0%, specificity: 50.0%, <i>P</i> = .033) fairly differentiated clinically relevant gastric varices (CRGVs) from non-CRGVs patients. Moreover, no correlation was noted between PHG and CREVs (<i>r</i> = .016, <i>P</i> <i>=</i> .778) or between PHG and CRGVs (<i>r</i> = -.024, <i>P</i> = .666). Furthermore, no difference in the severity of PHG before and after variceal eradication was detected (<i>P</i> = .224).</p><p><strong>Conclusion: </strong>The studied markers revealed poor to no ability to assess EGVs or PHG. Hence, they cannot be used to substitute EGD in the screening for EGVs. Furthermore, endoscopic eradication of EGVs did not affect the severity of PHG.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251339185"},"PeriodicalIF":3.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Procalcitonin as a Prognostic Biomarker in Hospitalized COVID-19 Patients: A Comparative Analysis.","authors":"Shahin Isha, Lekhya Raavi, Sadhana Jonna, Hrishikesh Nataraja, Emily C Craver, Anna Jenkins, Abby J Hanson, Prasanth Balasubramanian, Arvind Balavenkataraman, Aysun Tekin, Vikas Bansal, Swetha Reddy, Sean M Caples, Syed Anjum Khan, Nitesh K Jain, Abigail T LaNou, Rahul Kashyap, Rodrigo Cartin-Ceba, Ricardo Diaz Milian, Carla P Venegas, Anna B Shapiro, Anirban Bhattacharyya, Sanjay Chaudhary, Sean P Kiley, Quintin J Quinones, Neal M Patel, Pramod K Guru, Pablo Moreno Franco, Archana Roy, Devang K Sanghavi","doi":"10.1177/11772719241296624","DOIUrl":"10.1177/11772719241296624","url":null,"abstract":"<p><strong>Background: </strong>Procalcitonin (PCT) is recognized as an inflammatory biomarker, often elevated in COVID-19 pneumonia alongside other biomarkers. Understanding its association with severe outcomes and comparing its predictive ability with other biomarkers is crucial for clinical management.</p><p><strong>Objectives: </strong>This retrospective multicenter observational study aimed to investigate the association between PCT levels and adverse outcomes in hospitalized COVID-19 patients. Additionally, it sought to compare the predictive performance of various biomarkers.</p><p><strong>Design: </strong>The study analyzed data from the Society of Critical Care Medicine (SCCM) Viral Infection and Respiratory Illness Universal Study (VIRUS) registry, comprising COVID-19 patients hospitalized across multiple Mayo Clinic sites between March 2020 and June 2022.</p><p><strong>Methods: </strong>A total of 7851 adult COVID-19 patients were included. Patients were categorized into 6 groups based on the worst WHO ordinal scale. Multivariate models were constructed using peak biomarker levels within 72 hours of admission, adjusted for confounders.</p><p><strong>Results: </strong>Elevated PCT levels were independently associated with increased odds of adverse outcomes, including ICU admission (adjusted odds ratio [aOR] 1.32, 95%CI 1.27-1.38), IMV requirement (aOR 1.35, 95%CI: 1.28-1.42), and in-hospital mortality (aOR 1.30, 95%CI: 1.22-1.37). A 3.48-fold increase in IMV requirement and 3.55 times increase in in-hospital mortality were noted with peak PCT ⩾ 0.25 ng/ml. Similar associations were observed with other biomarkers like NLR (AUC 0.730), CRP, IL-6, LDH (AUC 0.800), and D-dimer (AUC 0.719). Models incorporating NLR, LDH, D-dimer, and PCT demonstrated the highest predictive accuracy, with a combined model exhibiting an area under the curve (AUC) of 0.826 (95%CI 0.803-0.849).</p><p><strong>Conclusions: </strong>Higher PCT levels were significantly linked to worse outcomes in COVID-19 patients, emphasizing its potential as a prognostic marker. Biomarker-based predictive models, particularly those including PCT, showed promising utility for risk assessment and clinical decision-making. Further prospective studies are warranted to validate these findings on a larger scale.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719241296624"},"PeriodicalIF":3.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹⁸F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels.","authors":"Ko-Han Lin, Tzu-Chun Wei, Shu-Huei Shen, William Ji-Shien Huang, Mei-Hua Chuang, Nan-Jing Peng, Wen-Tao Huang, Yuh-Feng Wang","doi":"10.1177/11772719251324307","DOIUrl":"10.1177/11772719251324307","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) patients with biochemical recurrence (BCR) following radical prostatectomy or radiation therapy often present with very low prostate-specific antigen (PSA) levels (⩽0.5 ng/mL). Accurate detection of recurrence at such low levels is crucial for guiding treatment decisions.</p><p><strong>Objectives: </strong>To assess the diagnostic efficacy of [¹⁸F]PSMA-1007 PET/MR (PSMA-PETMR) in detecting BCR of PCa in patients with very low PSA levels.</p><p><strong>Design: </strong>A prospective study conducted between May 2021 and January 2023, with data subsequently analyzed retrospectively after a 2-year follow-up.</p><p><strong>Methods: </strong>The cohort comprised 157 PCa patients with BCR, of whom 52 had PSA levels ⩽ 0.5 ng/mL and underwent PSMA-PETMR imaging. The imaging protocol incorporated multiparametric MRI (mpMRI) and PET acquisitions, with lesion classification following PSMA-RADS version 1.0. Detection rates of recurrent lesions, including local recurrence, lymph node metastasis, and skeletal metastasis, were evaluated.</p><p><strong>Results: </strong>PSMA-PETMR exhibited a 63.5% detection rate for recurrent PCa at low PSA levels, surpassing traditional diagnostic methods. Thirty-four local recurrences, 12 metastatic lymph nodes, and 4 skeletal metastases were identified. Follow-up imaging enhanced the detection rate to 73.1% by reclassifying initially equivocal findings. PSMA-PETMR influenced clinical decision-making in 17% of patients by facilitating personalized treatment strategies.</p><p><strong>Conclusion: </strong>PSMA-PETMR significantly improves the detection of recurrent PCa in patients with very low PSA levels, offering precise lesion localization and supporting personalized treatment approaches. Further studies are needed to optimize its clinical use and validate its long-term benefits.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251324307"},"PeriodicalIF":3.4,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Downregulation of DNAJC12 Expression Predicts Worse Survival for ER-Positive Breast Cancer Patients.","authors":"Pedro Henrique Fernandes Gatti, Flavia Regina Rotea Mangone, Ana Carolina Pavanelli, Suely Nonogaki, Cynthia Aparecida Bueno de Toledo Osorio, Vera Luiza Capelozzi, Maria Aparecida Nagai","doi":"10.1177/11772719251323095","DOIUrl":"10.1177/11772719251323095","url":null,"abstract":"<p><strong>Background: </strong>DNAJC12 (DnaJ heat shock protein family (Hsp40) member C12) encodes a member of the molecular chaperone Hsp40/DnaJ family, which are important protein folding and proteostasis regulators. Its role as a biomarker has been studied for a limited number of cancer types. Objectives: Here, we sought to investigate the potential of DNAJC12 mRNA and protein expression as a prognostic and predictive biomarker for breast cancer (BC).</p><p><strong>Methods: </strong>Using in silico analysis and data from immunohistochemistry analysis (IHC) of 292 samples from patients with primary BC, we determined the expression pattern and prognostic value of DNAJC12 mRNA and protein expression.</p><p><strong>Results: </strong>From online publicly available data, we were able to identify the transcripts of DNAJC12 as differentially expressed in patients with different clinicopathological characteristics, such as ER status (<i>P</i> < .001), PR status (<i>P</i> < .001), HER2 status (<i>P</i> < .010) and molecular subtype (<i>P</i> ⩽ .001). We also found DNAJC12 to be a potential prognostic predictor for overall survival, disease-free survival, and responsiveness to treatment; a low DNAJC12 mRNA expression is commonly associated with a worse prognosis. Using IHC analysis, we showed that low DNAJC12 protein-level expression is also associated with a worse prognosis in patients with all subtypes of BC and patients with Luminal BC, and its expression is significantly different between patients with different tumor size classifications (T1/T2 vs T3/T4; <i>P</i> = .013) or with different lymph node involvement (N0 vs N+; <i>P</i> = .005).</p><p><strong>Conclusion: </strong>Our findings suggested a potential role for DNAJC12 as a prognostic and predictive biomarker for BC.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251323095"},"PeriodicalIF":3.4,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11851741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143504812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelin-1 as a Candidate Biomarker of Systemic Sclerosis: A GRADE-Assessed Systematic Review and Meta-Analysis With Meta-Regression.","authors":"Arduino A Mangoni, Angelo Zinellu","doi":"10.1177/11772719251318555","DOIUrl":"10.1177/11772719251318555","url":null,"abstract":"<p><strong>Background: </strong>There is an ongoing search for novel biomarkers of vascular dysfunction, extent of fibrosis and organ involvement in systemic sclerosis (SSc).</p><p><strong>Objectives: </strong>We critically appraised the studies investigating the circulating concentrations of endothelin-1 in SSc patients and healthy controls.</p><p><strong>Design: </strong>This was a systematic review with meta-analysis.</p><p><strong>Data sources and methods: </strong>We searched electronic databases (PubMed, Scopus, and Web of Science) from inception to 15 June 2024. We assessed the risk of bias and the certainty of evidence using the JBI Critical Appraisal Checklist and GRADE, respectively.</p><p><strong>Results: </strong>Endothelin-1 concentrations were significantly higher in SSc patients than in controls (26 studies; standardised mean difference, SMD = 0.98, 95% CI 0.73-1.23, <i>P</i> < .001; moderate certainty of evidence). In SSc patients, there were no significant differences in endothelin-1 concentrations between those with limited and diffuse cutaneous SSc (10 studies; SMD = 0.32, 95% CI -0.07 to 0.71 <i>P</i> = .11; very low certainty), and with and without digital ulcers (5 studies; SMD = 0.82, 95% CI -0.06 to 1.69, <i>P</i> = .066; very low certainty), pulmonary arterial hypertension (7 studies; SMD = 0.22, 95% CI -0.01 to 0.45, <i>P</i> = .066; very low certainty) or interstitial lung disease (3 studies; SMD = 0.09, 95% CI -0.18 to 0.35, <i>P</i> = .51; very low certainty). There was limited evidence in SSc patients with different video capillaroscopy pattern and telangiectasias. Subgroup and meta-regression analyses showed significant associations between the effect size and geographical location (studies investigating SSc patients and controls), year of publication (studies investigating SSc patients with limited and diffuse cutaneous SSc), and biological matrix assessed (studies investigating SSc patients with and without digital ulcers).</p><p><strong>Conclusion: </strong>The results of this systematic review and meta-analysis highlight the potential role of endothelin-1 as a candidate biomarker of SSc. Further research is warranted to determine the utility of measuring endothelin-1 in SSc subgroups with different extent of fibrosis and organ involvement.</p><p><strong>Registration: </strong>PROSPERO registration number - CRD42024566461.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251318555"},"PeriodicalIF":3.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer.","authors":"Maike Zheng, Mingming Hu, Yanxia Liu, Xiaomi Li, Guirong Wang, Tongmei Zhang, Yan Zhao","doi":"10.1177/11772719251319641","DOIUrl":"10.1177/11772719251319641","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) hold a great promise in treatment of non-small cell lung cancer (NSCLC), while only a portion of patients benefited from the treatment, and others could not achieve optimal therapeutic effects from initial immunotherapy, even for those patients with PD-L1 (Programed cell death ligand 1) tested positive. However, the clinical markers for the selection of patients who will benefit from ICIs combination treatment beforehand are largely unknown.</p><p><strong>Objectives: </strong>The purpose of this study was to explore the non-invasive biomarkers that can predict the efficacy of immune combination therapy in advanced/metastatic NSCLC patients.</p><p><strong>Design: </strong>This study employed a retrospective cohort design to analyze dual predictive biomarkers in advanced non-small cell lung cancer (NSCLC) patients with immune combination therapy.</p><p><strong>Method: </strong>An analysis was conducted on baseline information of 144 patients with advanced/metastatic NSCLC who received ICIs treatment from the November of 2018 to the January of 2023 in Beijing Chest Hospital. We established a scoring group chart to make quantitative prediction for overall survival (OS) and progression-free survival (PFS) based on 4 variables, and set up the nomogram model as well as Decision curve analysis (DCA) to assess clinical benefits of ICIs combination in treatment of patients with advanced/metastatic NSCLC.</p><p><strong>Results: </strong>We found that serum globulin (GLB) >26.6 (g/L) (HR = 1.865, <i>P</i> = .002), absolute neutrophil counts (ANC) (10⁹/L) > 5 (HR = 2.146, <i>P</i> < .001), and bone metastasis (HR = 2.148, <i>P</i> < .001) were independent factors affecting the PFS of NSCLC patients. GLB > 26.6 (g/L) (HR = 1.741, <i>P</i> = .018), ANC (10⁹/L) >5 (HR = 1.807, <i>P</i> = .008), bone metastasis (HR = 1.651, <i>P</i> = .002), and PD-L1 Negative (HR = 2.432, <i>P</i> = .032) were independent factors affecting the OS of NSCLC patients. Same variables and cut-off value have good predictive efficacy in both PFS and OS.</p><p><strong>Conclusion: </strong>In patients with advanced/metastatic NSCLC receiving ICIs combination treatment, the GLB, ANC, bone metastasis, and PD-L1 may serve as useful predictive markers for the prognosis of NSCLC patients with ICIs combination treatment.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251319641"},"PeriodicalIF":3.4,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Comparative Analysis of Biomarkers in Type 2 Diabetes Patients With and Without Comorbidities: Insights Into the Role of Hypertension and Cardiovascular Disease\".","authors":"","doi":"10.1177/11772719251316045","DOIUrl":"https://doi.org/10.1177/11772719251316045","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/11772719231222111.].</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251316045"},"PeriodicalIF":3.4,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}